Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Demand normalisation post the second wave contributed to the steady growth
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company has strong product launches both in India and overseas
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
The collaboration will support Canada with direct access to rapid pandemic response capabilities
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Nearly 6,000 patients have been treated with the drug since 2017
Subscribe To Our Newsletter & Stay Updated
